[go: up one dir, main page]

EP2015782A4 - Compositions et procédés permettant de moduler l'expression des gènes - Google Patents

Compositions et procédés permettant de moduler l'expression des gènes

Info

Publication number
EP2015782A4
EP2015782A4 EP07760600A EP07760600A EP2015782A4 EP 2015782 A4 EP2015782 A4 EP 2015782A4 EP 07760600 A EP07760600 A EP 07760600A EP 07760600 A EP07760600 A EP 07760600A EP 2015782 A4 EP2015782 A4 EP 2015782A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
gene expression
modulating gene
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07760600A
Other languages
German (de)
English (en)
Other versions
EP2015782A2 (fr
Inventor
Dusan Stanojevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crosslink Genetics Corp
Original Assignee
Crosslink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crosslink Genetics Corp filed Critical Crosslink Genetics Corp
Publication of EP2015782A2 publication Critical patent/EP2015782A2/fr
Publication of EP2015782A4 publication Critical patent/EP2015782A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP07760600A 2006-04-12 2007-04-12 Compositions et procédés permettant de moduler l'expression des gènes Withdrawn EP2015782A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130506P 2006-04-12 2006-04-12
PCT/US2007/066571 WO2007121326A2 (fr) 2006-04-12 2007-04-12 Compositions et procedes permettant de moduler l'expression des genes

Publications (2)

Publication Number Publication Date
EP2015782A2 EP2015782A2 (fr) 2009-01-21
EP2015782A4 true EP2015782A4 (fr) 2010-04-07

Family

ID=38610393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07760600A Withdrawn EP2015782A4 (fr) 2006-04-12 2007-04-12 Compositions et procédés permettant de moduler l'expression des gènes

Country Status (3)

Country Link
EP (1) EP2015782A4 (fr)
CA (1) CA2649114A1 (fr)
WO (1) WO2007121326A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233173B2 (en) * 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2436398B1 (fr) * 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Conjugués d'amatoxine avec liens améliorés
CA2875945A1 (fr) 2012-06-07 2013-12-12 The Children's Hospital Of Philadelphia Procedes d'expression controlee de genes
EP2774624A1 (fr) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Dérivés d'amatoxine
CN105377304B (zh) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 鹅膏毒肽衍生物
KR20190038537A (ko) 2016-06-17 2019-04-08 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
EP3738608A4 (fr) * 2017-08-18 2021-12-08 Sichuan Baili Pharm Co. Ltd Conjugué d'anticorps de type amatoxine non-naturelle
EP4259643A4 (fr) * 2020-12-08 2025-01-15 The University of British Columbia Analogues d'amatoxine et leurs utilisations
WO2024036143A2 (fr) * 2022-08-09 2024-02-15 Ptc Therapeutics, Inc. Procédés de modulation d'épissage d'arn

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANSARI A Z ET AL: "TOWARDS A MINIMAL MOTIF FOR ARTIFICIAL TRANSCRIPTIONAL ACTIVATORS", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 8, no. 6, 1 January 2001 (2001-01-01), pages 583 - 592, XP001031162, ISSN: 1074-5521 *
ARORA PARAMJIT S ET AL: "Design of artificial transcriptional activators with rigid poly-L-proline linkers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 44, 6 November 2002 (2002-11-06), pages 13067 - 13071, XP007911805, ISSN: 0002-7863 *
INGLES C J ET AL: "ALPHA AMANITIN RESISTANCE OF RNA POLYMERASE II IN MUTANT CHINESE HAMSTER OVARY CELL LINES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 251, no. 9, 1976, pages 2729 - 2734, XP007911801, ISSN: 0021-9258 *
KUZNETSOVA S ET AL: "Gene activation by triplex-forming oligonucleotide coupled to the activating domain of protein VP16", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 20, 15 October 1999 (1999-10-15), pages 3995 - 4000, XP002222219, ISSN: 0305-1048 *
KWON YOUNGJOO ET AL: "Small molecule transcription factor mimic", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 49, 15 December 2004 (2004-12-15), pages 15940 - 15941, XP007911804, ISSN: 0002-7863 *
STANOJEVIC D ET AL: "A highly potent artificial transcription factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 41, no. 23, 11 June 2002 (2002-06-11), pages 7209 - 7216, XP002222221, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
CA2649114A1 (fr) 2007-10-25
WO2007121326A3 (fr) 2008-12-24
WO2007121326A2 (fr) 2007-10-25
EP2015782A2 (fr) 2009-01-21

Similar Documents

Publication Publication Date Title
ZA200908481B (en) Compositions and methods for altering gene expression
EP2052085A4 (fr) Procédés de modulation de set et utilisations associées
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL250678A0 (en) Compounds and methods for repressing pcsk9 gene expression
IL194788A0 (en) Compositions and methods for modulating vascular development
IL202184A0 (en) Methods and compositions for increased transgene expression
EP2066687A4 (fr) Compositions et procédés servant à inhiber l'expression du gène hamp
IL194814A0 (en) Mglur5 modulators i
EP2101731A4 (fr) Procédés et compositions d'endoxifène
PT2129680E (pt) Composições combinadas de gancho de cabelo e antissentido e métodos para modulação da expressão
ZA200807714B (en) Gene disruptions, compositions and methods relating thereto
EP2015782A4 (fr) Compositions et procédés permettant de moduler l'expression des gènes
IL205248A0 (en) Compositions and methods for making androstenediones
AU2007291030A8 (en) Novel compositions and methods
ZA200808498B (en) Novel gene disruptions,compositions and methods relating thereto
EP2018443A4 (fr) Compositions et méthodes inhibant l'expression du gène ikk-b
EP2205271A4 (fr) Compositions et procédés pour des thérapies à base de ribonucléase
PL2132251T3 (pl) Kompozycja i sposób
GB0610009D0 (en) Culture medium
EP2183380A4 (fr) Procédés et compositions pour une pcr
GB0608844D0 (en) Enzyme inhibitors
GB0625208D0 (en) Composition and method
GB0617161D0 (en) Enzyme inhibitors
GB0600261D0 (en) Composition and method
GB0604315D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101ALI20090120BHEP

Ipc: A61K 38/00 20060101ALI20090120BHEP

Ipc: C12Q 1/02 20060101ALI20090120BHEP

Ipc: C12Q 1/68 20060101AFI20090120BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100304

17Q First examination report despatched

Effective date: 20100616

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CROSSLINK GENETICS CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140805